Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
GRASSROOT
2 other identifiers
observational
459
1 country
1
Brief Summary
The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease, outside of a clinical study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2024
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 12, 2024
CompletedFirst Posted
Study publicly available on registry
July 18, 2024
CompletedStudy Start
First participant enrolled
December 5, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2032
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2034
March 12, 2026
March 1, 2026
7.6 years
July 12, 2024
March 10, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Overall Survival
Prospective real-world, large-scale, comprehensive data on these patients who are unable to access traditional clinical trials but are treated with MDA regimens, assigned by stage and BRAF-status.
Through study completion; an average of 1 year.
Eligibility Criteria
MD Anderson Cancer Center
You may qualify if:
- All adult patients aged 18 years or older (with the exception of certain external participant countries where the legal adult age may be different; for example in Singapore, adult majors are defined by age 21 and older) with anaplastic thyroid cancer or poorly differentiated thyroid cancer as their clinical and/ or histological diagnosis will be included.
You may not qualify if:
- Patients who do not have anaplastic thyroid cancer or poorly differentiated thyroid cancer on their tumor tissue would be excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Priyanka C Iyer, MBBS
M.D. Anderson Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 12, 2024
First Posted
July 18, 2024
Study Start
December 5, 2024
Primary Completion (Estimated)
July 1, 2032
Study Completion (Estimated)
July 1, 2034
Last Updated
March 12, 2026
Record last verified: 2026-03